We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Role of Enhancer of Zeste Homolog 2 Polycomb Protein and Its Significance in Tumor Progression and Cell Differentiation

Irene Marchesi and Luigi Bagella

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/55370>

1. Introduction

Epigenetics is a branch of genetics that focuses on the heritable changes of DNA or associated proteins, other than DNA sequence variations, which carry information content during cell division [1,2]. These heritable changes are ascribed to chromatin, which constitutes the ultrastructure of DNA and whose modifications affect the genetic material functionality. Differences in chromatin structure have been associated to transcription regulation [3-5] and chromosome stability [6,7], affecting both gene's information, expression and heritability. Noteworthy, these epigenetic modifications are involved in both transcriptional activation and repression, indicating their widespread role as modulators of gene expression in numerous biological processes [8,9].

Chromatin is subjected to numerous modifications roughly classified in two groups: DNA and histone post-translational modifications (histone-PTMs).

DNA methylation is the most studied epigenetic modification of DNA and corresponds to the covalent addition of a methyl (CH_3) group to the nucleotide cytosine within CG dinucleotides or CNG trinucleotides where N can be C, A, G or T. Usually, DNA methylation induces decreased protein-DNA binding of transcription factors and leads to the repression of gene expression [10].

DNA "methylable" sequences are not uniform across the human genome but restricted in CpG rich DNA regions termed CpG islands (CGI). CGI are localized at repetitive sequences, heavy methylated, to prevent the reactivation of endoparasitic sequences such as transposons, and at gene promoter sequences, which are normally refractory to methylation in normal somatic cells [8,11].

DNA methylation is specifically established by DNA methyltransferases proteins (DNMTs), which can be recruited by numerous DNA-binding molecular complexes. These enzymes were classically classified in two categories: *de novo* DNMTs, as mammalian DNMT3a and DNMT3b, in charge of the addition of the methyl group on a previously unmethylated DNA, and maintenance DNMTs, whose only known member is DNMT1, responsible for methylation renewal in the newly synthesized DNA copy. However, this classification does not entirely explain methylation establishment and maintenance in various molecular processes [10]. For instance, a number of studies demonstrated that all DNMTs are important in the maintenance of methylation during DNA replication, therefore indicating that it is not possible to distinguish classes of DNMTs based on their functional role [12-15]. Another important functional role in DNA methylation dynamics is constituted by the removal of methyl group, which is required to activate methylated genes. However, demethylation is a process not fully understood, in fact, until recently, it was current opinion that only a passive demethylation could occur, as a consequence of a lack of methylation maintenance during DNA replication. The discovery of several putative demethylases, as thymine DNA glycosylase (TDG), methyl-binding domain 2 (MBD2), and GADD45 [16-18], strongly suggested that an active mechanism of demethylation can occur in specific contexts, such as germ line reprogramming [19-22].

The second group of epigenetic changes is represented by histone post-translational modifications (PTM), which consist in the addition of chemical groups to amino acid residues of both canonical histones (H2A, H2B, H3 and H4) and variant histones (such as H3.1, H3.3 and HTZ.1).

Differently from DNA modifications, there are at least eight distinct types of histone post-translational modifications: acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, deimination, and proline isomerization. Each chemical group can be established at multiple amino acid residues of nucleosomes in multiple levels of substrate modification by specific classes of enzymes. For example, lysine methylation can be established at numerous aminoacidic residues of N-terminus tails of histones H3 and H4, such as K4, K9, K20 and K27, in mono-, di- or tri-methylated forms. This variety of histone PTMs and its timing of appearance depends on the particular cell conditions giving the cells different functional responses [23]. Differently from DNA methylation, histone PTMs feature numerous functional roles. For instance, histone acetylation regulates DNA replication, repair and condensation; methylation, phosphorylation and ubiquitylation are involved in DNA repair or condensation. Moreover, all PTMs regulate transcription processes; acetylation is generally a marker of transcriptionally active genes, and methylation can be a marker of repressed or active genes depending on the amino-acid residues involved. For example, methylation of histone H3 lysine 4 (H3K4me) is considered a mark of transcriptionally active genes, while methylation of histone H3 lysine 9 and 27 (H3K9me; H3K27) are considered a mark of transcriptionally repressed genes [8,11,23].

Almost all cellular processes that require transcription dynamics and genetic stability can be considered epigenetic processes. Cellular differentiation is a good example of biological process, which is strictly connected to epigenetics. The genome sequence is static and it is the same for each cell of an organism (with some exceptions); however, cells are able to differentiate into many different types, with different morphology and physiological functions. During organism

development, the zygote, derived from a single fertilized egg cell, originates totipotent cells, able to potentially differentiate in all cell types of adult organisms. After several divisions, totipotent cells originate pluripotent cells, which are partially differentiated and able to differentiate in several cell types. Finally, pluripotent cells complete differentiation becoming adult somatic cells. The differentiation processes are characterized by transcriptional activation and repression of specific genes and, once completed, the cells maintain their characteristic gene-expression pattern, strictly dependent on the epigenetic modifications previously established [24]. Therefore, cell differentiation is rigorously related to the establishment of the correct epigenetic status and to the proper epigenetic maintenance. Epigenetic abnormalities alter gene expression, counteracting regular differentiation and cell physiology [25]. In support of this theory, cancer cells feature an aberrant epigenetic landscape, indicating the causal relationship between epigenome dynamics and cellular processes as proliferation, cellular identity maintenance and genomic instability. [26-28]. Frequently, CGIs in the proximity of tumor suppressor genes (TSG) are methylated in various cancers, inducing TSGs transcriptional repression and promoting cancer progression [29]. Furthermore, specific patterns of histones H3 and H4 acetylation and methylation are associated with numerous cancer types, and it has been shown that several epigenetic patterns enable to distinguish disease subtypes [30,31].

This chapter explores the role of the Enhancer of Zeste Homolog 2 (EZH2). EZH2, the catalytic subunit of Polycomb repressive complex 2, catalyzes the addition of methyl groups to lysine 27 of the N-tail of histone H3 (H3K27me). The importance to specifically focus on EZH2 raises from the evidence that it is involved in several differentiation processes and is often over-expressed in a wide variety of cancer types [32].

2. PcG proteins and PRC-mediated silencing

Polycomb group proteins (PcG) were discovered in *Drosophila melanogaster* as responsible of homeotic gene silencing, also referred as Hox clusters. Hox proteins are a group of transcription factors that determine cell identity along the anteroposterior axis of the body plan by the transcriptional regulation of hundreds of genes [33-42]. After the initial discovery in fruit flies, PcG proteins were detected in plants and in mammals, where they are involved in development, stem cell biology and cancer [43-48]. Polycomb-mediated gene silencing is required in many processes like mammalian X-chromosome inactivation and imprinting [49,50]. Furthermore, PcG proteins are required to maintain stem cell identity [51]. Indeed, their numerous target genes encode for transcription factors and signaling components involved in cell fate decision, therefore in differentiation processes [32].

Principal PcG proteins are conserved from *Drosophila* to human indicating that PcG-mediated gene silencing is conserved among eukaryotes [42,52,53]. In mammals, each of the fly proteins has two or more homologs [54]. PcG proteins form two main complexes: Polycomb-repressive complex 1 and 2 (PRC1, PRC2) [55-59].

In mammals PRC1 is formed by BMI1, RING1A/B, CBX, and PHC subunits [60]. RING1A/B are ubiquitin E3 ligases that catalyze the monoubiquitylation of histone H2A at lysine 119 (H2AK119ub1), a histone PTM associated with transcriptional silencing [48,53].

As previously explained, PRC2 has a histone methyltransferase activity on lysine-27 of histone H3 [56-59]. EZH2 is the catalytic subunit of the complex and is activated by other PRC2 subunits like EED, SUZ1 and RbAp46 [61,62]. Recent studies have identified an EZH2 homolog, EZH1 that originates an alternative PRC2 complex and, as EZH2, is able to methylate H3K27. EZH1 and EZH2 can occupy similar target genes, and in some cases have been proposed to play redundant roles. However, during development, it has been demonstrated that the two proteins, can also have distinct and context-dependent roles [63-65].

PRC1 and PRC2 are able to induce gene silencing independently by each other [66,67] or by a synergistic mechanism. In fact, establishment of H3K27me3 by PRC2 complex can induce the recruitment of PRC1 by binding the chromodomain of the PHC subunits [39,58]. Once recruited, PRC1 induces transcriptional repression of target gene by catalyzing the ubiquitylation of lysine 119 of histone H2 or by an H2Aub-independent mechanism [68-70]. Therefore, in gene promoters of PRC1 and PRC2 common target genes, H3K27me3, can be reckoned as the hallmark of PcG mediated repression, whereas PRC1 carries out the gene silencing (Figure 1) [48,71].

Figure 1. Epigenetic gene silencing PcG-mediated. PRC2 induces EZH2-mediated H3K27me3. H3K27me3 recruits PRC1 that ubiquitylates H2AK119 promoting chromatin compaction and gene silencing.

For what concerns PRC1-independent target genes, it has been shown that PRC2 is able to catalyze *in vitro* the methylation of lysine 26 of histone H1, which in turn recruits heterochromatin binding protein 1 (HP1) to chromatin, influencing its structure [72,73].

PRC2 is also able to cooperate with other epigenetic silencing enzymes. Recent studies demonstrated that it acts upstream of DNMTs in order to silence target genes [74]. The mechanism is not yet clear, but a hypothesis is that target genes are initially repressed through histone H3K27 methylation. Afterwards, PRC2 induces a more stable transcriptional silencing by recruiting DNMTs and establishing CGI methylation [75-77]. Moreover, PRC2 associates with histone deacetylases, reinforcing transcriptional repression and providing functional synergy to stable silencing of target genes (Figure 2) [32,56-59,61,78,79].

The functional link between PcG proteins, HDACs and DNMTs demonstrated a synergic control of gene silencing involved in both physiological and pathological processes.

Figure 2. Functional link between PRC2 HDACs and DNMTs. Target genes are initially deacetylated by a histone deacetylase. PRC2 silences target genes by H3K27me3. PRC2 may also recruit DNMTs that methylate DNA promoting a more strongly silenced chromatin state.

3. Regulation of PRC2 activity

Polycomb group proteins are epigenetic regulators of embryonic development and stem cell maintenance [48,51,80] and their deregulation contributes to cancer [28,81]. The crucial role of Polycomb-repressive complexes in the regulation of these biological processes strongly supports the presence of multiple molecular mechanisms involved in PRC activity modulation, such as regulation of expression, post-translational modification and recruitment of other molecular complexes to target genes.

3.1. Regulation of PRC2 components expression

As already explained, PRC2 functions are strictly tissue-specific. Therefore, it should not surprise that the expression of PRC2 subunits has been reported to be context- and tissue-specific, despite the activity of PRC2 promoters has not yet fully understood. Recently, it has been proposed a general rule by which PRC2 expression is maintained by molecular factors that control cell proliferation and self-renewal, such as E2F factors and c-myc, whereas its transcriptional repression is induced by differentiation-promoting factors, such as pRb and p16INK4b [65,82-85].

For what concerns the transcriptional regulation by the pRb/E2F pathway, it has been demonstrated that E2F factors are required for the transcriptional activity of EZH2 and EED in mouse embryonic fibroblasts (MEF). Ectopic expression of pRb and p16INK4b, both involved in E2F target gene repression, induces PRC2 subunits transcriptional repression, whereas pRb silencing increases their transcript levels [82-84].

Furthermore, it has been recently reported that c-myc, a key regulator of ES cells pluripotency maintenance, is directly involved in transcriptional upregulation of all components of PRC2; c-myc binds PRC2 subunits promoters and induces the acetylation of histones H3 and H4, an epigenetic modification involved in transcriptional activation [85].

Finally, it has been demonstrated that EZH2 is post-transcriptionally regulated by a microRNAs-mediated translation-inhibition mechanism. MicroRNAs (miRNAs) are small non-coding RNA ~22 nt long (ncRNA), involved in various biological processes, which exert gene expression regulation. Several studies showed a role of miRNA in chromatin structure, they are indeed able to regulate transcriptional levels of epigenetic enzymes as for example PcG proteins [86,87]. Initially, it has been shown that miRNA-101 and miRNA-26a negatively regulate EZH2 expression by binding to its 3'-UTR. However, recent studies have reported an increasing number of miRNAs, able to inhibit the translation of PRC2 subunits (reviewed in [87]). For example, miR-214 regulates EZH2 expression during muscle differentiation [88]. Furthermore, downregulation of several miRNAs promotes EZH2 overexpression in cancer; for instance, miR-25 and miR30d in thyroid carcinoma [89], let-7 in prostate cancer [90], miR-98 and miR-214 in esophageal squamous cell carcinoma.

3.2. Post-translational modification of EZH2

Several studies demonstrated that post-translational modifications of PRC2 subunits can regulate their recruitment to target genes and molecular activity [91-93].

The first post-translational modification that will be analyzed is EZH2 phosphorylation, which has been extensively studied. In order to bind to PRC2 complex and exert its molecular function, EZH2 must be phosphorylated in several specific sites. EZH2 phosphorylation can be classified in two groups: dependent by cell-cycle-dependent signals and dependent by extracellular-regulated kinases [94]. In the first mechanism, EZH2 is phosphorylated by Cdk1 and Cdk2 during cell cycle progression [92,93,95]. In murine model, phosphorylation of threonine 345 (Thr345) increases the binding of EZH2 to specific regulatory ncRNAs as HOTAIR that induces the recruitment of PRC2 to HOX gene promoters, and Xist RepA that

induces the inactivation of X chromosome [93]. In humans, phosphorylation of threonine 350 (Thr350) corresponds to murine Thr345. Recently, Chen *and collaborators* demonstrated a crucial role for the phosphorylation of Thr350 by Cdk1 and Cdk2 in both EZH2-dependent gene silencing and EZH2-mediated cell proliferation and migration [92].

Moreover, Cdk1 is able to phosphorylate EZH2 at Thr487. This modification is associated with the disruption of EZH2 binding with other PRC2 components with subsequent methyltransferase activity inhibition [95]. Surprisingly, these data are in contrast with studies of Kaneco *and coworkers*, which demonstrated that EZH2 phosphorylated at Thr487 is able to bind other subunits of PRC2 complex and to maintain its activity. In addition, another recent work showed that inhibition of Cdk1 suppresses *hoxA* gene expression in contrast to the findings of Chen *and colleagues*. [92,93,95]. Bearing in mind that these three findings use different models to analyze EZH2 phosphorylation, becomes noticeable that the apparent discrepancies could be explained with different mechanisms of tissue-specific regulation. Further studies are needed to resolve these specific incongruities. Mechanisms of EZH2 regulation during cell cycle are summarized in figure 3.

Figure 3. Model for regulation of EZH2 activity during cell cycle. PRC2 subunits are E2Fs target genes. E2Fs activity is inhibited by hypo-phosphorylated pRb during G1 phase of cell cycle. Activity of Cdk/cyclin complexes triggers the transition from G1 to S phase through phosphorylation of pRb and consequent activation of E2F target genes. Moreover Cdk2 and Cdk1 are able to phosphorylate EZH2 promoting the binding of ncRNA, a crucial step for the recruitment of PRC2 to its target genes.

Phosphorylation of EZH2 is also modulated by environmental signals. Extracellular signals induce Akt activation that in turn is able to phosphorylate EZH2 at Serine 21 (Ser21), which results in a suppression of the PRC2 activity. Differently by previous phosphorylation mechanisms, Akt-dependent phosphorylation does not affect the binding with other PRC2

components but it reduces the affinity of EZH2 with histone H3, which results in a decrease of the H3K27 methylation and consequent de-repression of the EZH2-silenced genes [96].

Furthermore, recent studies reported that EZH2 can be phosphorylated at threonine 372 (Thr372) by p38 α kinase in muscle stem (satellite) cells in response to tumor necrosis factor (TNF), an inflammatory cytokine highly expressed in muscle regeneration process [97]. The phosphorylation of EZH2 at Thr372 promotes the repression of Pax7, a marker of stem cells, by inducing the interaction between PRC2, YY1 and PRC1. This leads to the transcriptional activation of genes involved in muscle regeneration and to transcriptional repression of genes involved in cell proliferation. This data are in apparent conflict with the fully studied role of EZH2 in the cell proliferation promotion, but it is possible that in response to specific signals and in particular cell types, PRC2 can silence genes involved in cell cycle regulation, resulting in an antiproliferative activity [97]. Other studies are needed to confirm this hypothesis.

Finally EZH2 and SUZ12 can be sumoylated *in vitro* and *in vivo* but the role of this modification is still not yet clear [91].

3.3. PRC2 recruitment to target genes

PRC2 core subunits bind to the DNA sequences with low affinity, this, therefore, suggests the existence of recruiting mechanisms that direct PRC2 to target genes [98].

In *Drosophila melanogaster*, PcGs are recruited by Polycomb response elements (PREs), DNA sequences of several hundred base pairs [42,48,99] located both in proximal region of gene promoters and in long-range enhancer elements. PREs contain consensus sequences for various transcription factors [100]. For instance, *Drosophila*'s pleiohomeotic (PHO) and pleiohomeotic-like (PHO-like) are PcG proteins conserved in mammalian cells and involved in the recruitment of PRC complexes.

It is important to stress that PREs are element and not short stretches of nucleotides and contain numerous TF binding sites, therefore, although several *Drosophila* transcription factors are essential for the recruitment of PRC complexes to specific promoters, a single TF is not sufficient alone. Moreover, "universal" factors able to bind all PcG target genes have not been found yet, and it is strongly suggested that the PcG protein recruitment is a cell type-specific mechanism dependent by various combinations of TFs [52,53]. Mammalian PREs have been just recently discovered [101]. The mammalian orthologue of *Drosophila* DNA-binding protein PHO is YY1, however, studies in mouse stem cells showed a little overlap between sequences bound by YY1 and PRC2 suggesting a cell-type specific role rather than a general one [47].

Similar to YY1, the embryonic stem (ES) cell-related transcription factors OCT4, SOX2 and NANOG co-occupy a subset of PcG target genes in human and mouse ES cells [45,46]. Interestingly, recent studies demonstrated that the serine/threonine protein phosphatase-1 (PP1), together with its regulatory partner NPP1, is capable of complexing PRC2 at its target genes, modulating the DNA occupancy of EZH2 and therefore its activity [102].

Current data suggest that, similarly to flies, various transcription factors may be involved in the recruitment of mammalian PRC2, varying in different cell types and context. Recent studies

showed that Twist-1 recruits EZH2 at ARF-INK4a locus in Mesenchymal Stem Cells (MSCs), inducing transcriptional repression of both p14ARF and p16INK4a, and suppression of senescence initiation [103].

Moreover, PRC2 can also be associated with another PcG protein, called PHF1. PHF1 is not a core subunit of PRC2 but its association with the complex influences the recruitment of PRC2 to target genes and stimulates the enzymatic activity [104,105].

Furthermore, several reports have identified in mouse and human ES cells, a novel DNA-binding component of PRC2 complex, Jarid2, which is a member of the Jumonji C (JmjC) family that binds GC and GA-rich motifs [106-109]. Despite this, it has been demonstrated that Jarid2 promotes PRC2 recruitment to target genes, but its precise role in PRC2 activity has not yet been defined. Knockdown of Jarid2 causes an increase of H3K27me3 levels on some PRC2-target genes [106,107] and a decrease on others [108,109]. Different effects of Jarid2 on PRC2 activity could depend from additional factors, and it has been suggested that it acts as a “molecular rheostat” that finely calibrates PRC2 functions at developmental genes [106].

Finally, long ncRNAs have been implicated in the recruitment of PRC2 [48,53,80,81,110]. For example, in primary human fibroblasts the ncRNA HOTAIR recruits PRC2 complex to HOXD locus for regulating gene silencing in *trans* [111]. Several long ncRNA have been discovered and its tissue-specific expression allows assuming PRC2-dependent roles in organogenesis [112].

4. Role of PRC2 in differentiation and cell fate commitment

In past decades, several studies demonstrated that PcG proteins play a key role during invertebrate differentiation but, only recently, the involvement of these proteins during vertebrate organogenesis as regulators of developmental gene expression has been confirmed. Various tissues are regulated by PRC2 during development (Table 1).

Embryonic stem cells (ESC) are able to differentiate into all derivatives of the three primary germ layers and their pluripotency is preserved by the inhibition of differentiation and the promotion of proliferation [71]. Therefore, ESC can be an extremely valuable model to study cell fate transition mechanisms involved in mammalian development. As previously explained, during development, epigenetic changes regulate the activation determining cell fate.

Genome wide analysis revealed that epigenetic changes regulate the activation or the inhibition of lineage-specific transcription factors in cell fate transition, suggesting their role in the maintenance of ESC pluripotency. For what concerns the polycomb repressive complexes, they occupy gene promoter sequences of the main developmental genes, impeding their transcriptional activation through repressive marks [44-46].

Major targets of PRC2 are tumor suppressor genes, such as Ink4b/Arf/Ink4a locus and their inhibition promotes cell proliferation [44,132,136-141].

In ESC, numerous differentiation-related genes feature a bivalent epigenetic regulation in preparation of lineage commitment [65]. This bivalent epigenetic regulation consists in the

Tissue	Specie	Role/Stage	References
Brain	human mouse	Neuronal stem cell maintenance; oligodendrocytes differentiation	[113-118]
Spinal Cord	chicken	Dorsoventral patterning	[119]
Skin	human mouse	Epidermal stem cell maintenance; hair follicle homeostasis	[120-122]
Cardiac Muscle	mouse	Endocardial cushion formation and cardiomyocyte proliferation	[123-125]
Skeletal Muscle	mouse	Skeletal muscle stem cells maintenance; somites developing and myoblasts proliferation	[88,126-129]
Liver	mouse	Hepatic stem/progenitor cells proliferation and self-renewal	[130,131]
Pancreas	mouse	β -cell proliferation	[132,133]
Adipose Tissue	mouse	Adipogenesis promotion	[134]
Mammary Gland	mouse	Alveolar progenitors maintenance	[135]

Table 1. Tissues under PRC2 regulation

presence of both H3K27me3 and H3K4me3, which respectively are a repressing and an activating mark of transcription [142]. Upon differentiation, PRC2 complex dissociates from these gene promoters, inducing H3K27me3 removal and gene expression [45,46].

Similarly to ESC, PRC2 is involved in organ development through tissue-dependent mechanisms. As a general rule, EZH2 prevents differentiation by inhibiting genes involved in its completion. For instance, EZH2 negatively regulates skin development by repressing premature differentiation of skin progenitors. Specifically, it has been shown that in this specific differentiation model, EZH2 prevents epidermal differentiation by inhibiting the recruitment of AP1, a transcriptional activator, to Ink4/ARF locus, thus maintaining proliferative potential of epidermal progenitors [120]. Likewise, it has been reported that silencing of EZH2 in hepatic stem/progenitor cells promotes the differentiation into hepatocytes and further enhances the maturation of hepatocytes through Ink4a-Ink4b dependent and independent mechanisms [130].

EZH2 also contributes to pancreatic regeneration, by the suppression of Arf/Ink4a locus and the promotion of pancreatic β -cells proliferation, [132] and to terminal differentiation inhibition of mammary gland alveolar cells during pregnancy, in order to prevent milk production and secretion until parturition [135].

In opposition to PRC2-dependent mechanisms mentioned above, there are some tissues and organs, which require PRC2 activity for differentiation completion. For instance, recent studies showed a promoting role of EZH2 methyltransferase activity in adipogenesis. EZH2 is required, indeed, for silencing of Wnt1, -6, -10a, and -10b genes, which are inhibitors of adipogenesis [134]. Moreover, EZH2 contributes to the correct development by preventing the inappropriate gene expression, typical of different cell types. The cardiac differentiation is an example of this PRC2-dependent regulatory function; indeed, EZH2 is involved in transcrip-

tional repression of genes as *Six1*, responsible of skeletal muscle genes activation in cardiomyocytes. EZH2-knockout mice feature postnatal myocardial pathologies and altered cardiac gene expression [123,125]. EZH2 promotes evenly, by indirect mechanism, liver differentiation by the inhibition of *Pdx1* gene, which is involved in pancreatic differentiation promotion [133].

The complexity of PRC2-dependent molecular pathways in organogenesis has been specifically demonstrated by extensive studies in neurogenesis and myogenesis.

4.1. Role of EZH2 in neurogenesis

Neurons and astrocytes derive from common neural precursors (neuronal stem cells: NSC), which sequentially pass through phases of expansion, neurogenesis and astrogenesis. The timing of the switch from neurogenic to astrocyte differentiation is crucial for the determination of neuron numbers.

Analysis of EZH2 expression in neurogenesis showed that EZH2 decreases when NSCs differentiate into neurons and is completely suppressed in astrocyte differentiation. In contrast, EZH2 expression remains high in oligodendrocyte differentiation, from precursor cells to the immature stage [113]. EZH2 silencing and overexpression in NSCs confirmed these results, indeed forced expression of EZH2 increases the number of oligodendrocytes and reduces the number of astrocytes [113]. Furthermore, forced expression of EZH2 in astrocytes induces a partially dedifferentiation to NSCs [117], supporting a key role for EZH2 towards oligodendrocyte commitment. For what concerns EZH2 silencing, it has been reported that inhibition of EZH2 or EED in neural precursor cells extends neurogenic phase, inducing an increased production of neurons and a delay in gliogenesis [114]. However, Pereira and colleagues found that loss of EZH2 results in a shift from self-renewal towards differentiation, accelerating the timing for both cortical neurogenesis and gliogenesis [115]. These differences could be accounted to differential EZH2 inhibition timing before or after neurogenesis onset; further studies are required to clarify this pathway, but all data confirm an essential role for PRC2 in the regulation of developmental transitions timing.

4.2. Role of EZH2 in skeletal myogenesis

Proliferation and differentiation of skeletal muscle cells are controlled by a family of myogenic transcription factors, known as bHLH proteins. MyoD is one of the most important bHLH factors, which is crucial for complete muscle differentiation [143]. In ESC, PRC2 binds and represses numerous MyoD target genes [46]. In skeletal myoblasts, despite MyoD expression, PRC2 is recruited by YY1 to muscle-specific genes, inhibiting their expression and preventing premature differentiation. After the commitment of myogenesis, EZH2 expression decreases and H3K27me3 at MyoD-target loci is removed. Consequently, muscle-specific genes are transcriptionally active [126]. This process is finely regulated by miR-214, a miRNA expressed after myogenic commitment of MyoD. In myoblasts, PRC complexes occupy and repress transcription of the intronic region containing miR-214. During myogenesis decreased levels of EZH2 allow derepression of

the miR-214 locus. miR-214, on the other hand, targets EZH2 3'UTR reducing its mRNA translation, thus inhibiting EZH2 mRNA translation [88].

It has been shown that UTX, a specific demethylase that accomplish the muscle specific genes activation, is specifically involved in removal of H3K27me3 and in establishment of H3K4me3, an epigenetic marker of active genes [127].

Interestingly, EZH1 expression increases during myogenesis and its levels remain elevated in differentiated myoblasts [144]. It has been demonstrated that PRC2-EZH1 complex has a crucial role in the correct timing of transcriptional activation of muscle specific genes, as myogenin, allowing proper recruitment of MyoD on its target promoters. This mechanism involves another epigenetic modification, the phosphorylation of serine 28 of the histone H3 (H3S28ph), which is fundamental for the displacement of the PRC2-EZH2 complex [129].

This example proves the complexity of PRC2 dependent mechanism during development and demonstrates how distinctive complexes can regulates various stages of differentiation.

Despite the numerous roles of PRC2 in differentiation and organogenesis are attributable to a tissue-specific behavior, further studies are required to clarify each time its role in any process of differentiation.

It is certainly clear that both PRC2 and its catalytic subunit EZH2 can be defined as key factors in the regulation of development and in preserving cell identity.

5. EZH2 and cancer

Epigenetic abnormalities lead to altered gene expression and cellular physiology and occur in several pathologies such as cancer [145,146]. Cancer epigenetics is a branch of cancer biology that focuses on the epigenetic malfunctions involved in cancer initiation and progression [11]. EZH2 is differentially expressed in many tumors with abnormally elevated levels in cancer tissues versus the corresponding normal ones. Of interest is that EZH2 expression is generally correlated with metastatic cancer cells and poor prognosis [32].

Microarray studies in breast and prostate cancers were the first reports addressing the implication of EZH2 in tumor progression [79,147]. Currently, a wide number of human cancers associated with the deregulation of EZH2 have been discovered (Table 2).

The role of PcG proteins in cancer epigenetics is partially attributed to their contribution in transcriptional repression of INK4b-ARF-INK4a locus, which encode p15INK4b, p16INK4a and p14ARF proteins. These proteins constitute a homeostatic mechanism that protect organism from inappropriate growth signals, which would eventually lead to uncontrolled proliferation, promoting in contrast senescence or apoptosis [139]. Various tumors are characterized by mutations or transcriptional repression at INK4b-ARF-INK4a locus, which is frequently a consequence of an aberrant epigenetic landscape established by factors as EZH2.

p15INK4b and p16INK4a are cyclin-dependent kinase inhibitors (CdkI) that function upstream in the retinoblastoma protein (pRb) pathway. pRb can be found in two isoforms: hypo-

phosphorylated pRb is the biologically active form, while hyper-phosphorylated pRb is inactive. Hypo-phosphorylated pRb binds and inhibits E2F transcriptional factor activity. Cdks, through phosphorylation of pRb, render E2F an active transcriptional activator on the E2F target genes. INK4 proteins bind Cdk4 and Cdk6, blocking the assembly of catalytically active Cyclin–Cdk complexes.

The result of an elevated transcription of INK4 proteins is a pRb-dependent cell-cycle arrest in G1-phase [44,132,136-141,188,189]. Differently from INK4 proteins, p14ARF activates p53 pathway by inhibiting MDM2 functions. Indeed, MDM2 modulates p53 activity by inducing its transcriptional repression and by promoting its proteasome-mediated degradation. p14ARF induction generally causes cell-cycle arrest in G1 and G2 phases and apoptosis [139,190,191]. Interestingly, EZH2 activity on p16INK4a promoter is Rb family-dependent. Indeed, EZH2 is not able to bind INK4a locus in Rb proteins-deficient cells. A model has been proposed where pRb recruits PRC2 to the p16INK4a promoter, which in turn promotes its transcriptional repression [192].

EZH2 has shown a functional role even on pRb2/p130. pRb2/p130 is a member of Rb family that binds and recruits HDAC1 at Cyclin A promoter, inducing gene silencing. Cyclin A is a protein with a crucial role in cell cycle advancement. EZH2 competes with HDAC1 for its binding with pRb2/p130, disrupting both proteins occupancy on cyclin A promoter, inducing cyclin A activation and cell cycle progression [193,194].

As well as Rb family members, EZH2 inhibits tumor suppressor genes as p21 and phosphatase and tensin homolog (PTEN) [170,195]. For example, oncogenic stimuli in melanocytes provoke an oncogene-induced senescence, termed melanocytic nevus, which is a benign precursor of melanoma. EZH2 overexpressing cells escape senescence through the inhibition of p21. EZH2 depletion indeed, results in p21 activation and senescence induction in human melanoma cells [195]. A similar functional role has been reported in B-cell acute lymphoblastic leukemia (B-ALL) cells, where EZH2 overexpression induces p21, p53 and PTEN silencing whereas its knockdown induces cell cycle arrest and apoptosis [170].

As already stated, EZH2 is involved in apoptosis regulation [196,197]. High levels of EZH2 induce silencing of DAB2IP, a Ras GTPase-activating protein that promotes apoptosis through the tumor necrosis factor-mediated JNK signaling pathway [196], and Bim, a protein that promotes E2F1-dependent apoptosis [197].

DAB2IP is downregulated by epigenetic modifications in multiple aggressive cancers such as lung, breast and prostate. In medulloblastoma, EZH2-dependent-DAB2IP repression correlates significantly with a poor prognosis, independent by the metastatic stage [187].

Recent reports, using genome-wide technologies, reported that a large number of differentiation-related factors are PRC2-target genes [43-47]. Consequently, numerous differentiation-related factors as Gata, Sox, Fox, Pou, Pax, components of Wnt, TGF- β , Notch, FGF and retinoic acid pathways are silenced by EZH2 [32,44-46]. It has been proposed that similarly to ESC, the role of EZH2 in cancer is linked to its activity in self-renewal promotion and in the maintenance of undifferentiated state of cells; EZH2 deregulation indeed, strongly contributes to the transcriptional silencing of tumor suppressor and differentiation genes, promoting therefore

uncontrolled cell proliferation and cancer progression [32]. For instance, EZH2 is upregulated in Rhabdomyosarcoma (RMS) cell lines and primary tumors [180]. RMS is a tumor that arises from muscle precursor cells, characterized by a partial myogenic differentiation. RMS cells do not form functional muscle units and feature a strong proliferative ability. Specifically, as shown in a recent study, EZH2 binds and silences several muscle gene promoters evenly under differentiated conditions. The silencing of EZH2 promotes the reduction of H3K27me3 establishment, the recruitment of elongating RNA Polymerase II at these loci and the activation of muscle specific genes, with a partial recovery of skeletal muscle phenotype [182].

Finally, PRC2 complex inhibits the expression of several tumor suppressor miRNA. For instance, downregulation of miR-31, a common event of various melanomas, is caused by epigenetic silencing of EZH2-mediated histone methylation [177].

Moreover, in metastatic liver cancers, up-regulation of EZH2 inhibits miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b, promoting cell motility and metastasis-related pathways [163].

Cancer	Histological Origin	References
Breast	Epithelial	[84,147-151]
Prostate	Epithelial	[79,149,152-157]
Lung	Epithelial	[158-160]
Colon	Epithelial	[161]
Liver	Epithelial	[162,163]
Gastric	Epithelial	[164]
Lymphoma	Mesenchymal	[165-171]
Myeloma	Mesenchymal	[172-174]
Ovarian	Epithelial	[175]
Skin	Epithelial	[149,176,177]
Bladder	Epithelial	[178]
Endometrial	Epithelial	[149,179]
Sarcoma	Mesenchymal	[180-182]
Pancreas	Epithelial	[156,183,184]
Kidney	Epithelial	[185]
Brain	Nervous Tissue	[186,187]

Table 2. Human cancers associated with overexpression of EZH2

5.1. Extra-nuclear function of EZH2

The role of EZH2 as chromatin regulator has been extensively analyzed in a number of normal and pathological models. Recent studies demonstrated a localization of EZH2 and other PRC2

components in the cytoplasm of murine and human cells [198]. Cytoplasmic EZH2 maintains its methyltransferase activity and interacts with Vav1, a GDP-GTP exchange factor (GEF) for members of the Rho-family of GTPases. EZH2-Vav1 complex is necessary for actin reorganization and cellular proliferation in T-lymphocytes and fibroblasts, promoting cytoskeletal dynamics and cell migration as well as proliferation [198]. An example of this specific cytoplasmic function could be found in prostate cancer cells, characterized by increased levels of both nuclear and cytoplasmic EZH2. Cytoplasmic EZH2 might influence cell adhesion and migration, contributing to invasiveness and metastatic ability of tumors [199,200]. The nuclear and cytoplasmic functions of PRC2 thereby could co-operate to promote tumorigenesis.

5.2. Tumor suppressor roles of EZH2

Up to few years ago, EZH2 and PRC2 upregulation were assumed to hypermethylate H3K27, repressing the transcription of tumor suppressor genes. In 2010, Morin and colleagues identified a somatic mutation (Tyr641), which affects the EZH2 catalytic domain activity in diffuse large B-cell lymphoma but not in mantle cell or T-cell lymphoma. Specifically, mutations in lymphoma were heterozygous but haploinsufficient for the enzymatic activity, resulting in global deficit of H3K27 methylation and derepression of gene expression [168]. It has been supposed that the loss of EZH2 in lymphoma may lead to derepression of genes, promoting cell growth [201]. Other reports demonstrated that specific mutations in the EZH2 enzyme display limited capacity to carry out H3K27 monomethylation but have high efficiency for driving di- and tri-methylation. In B-cell lymphomas, mutant and wild type EZH2 co-operate increasing the trimethylated form [202].

Although the data analyzed as of now allow us to classify EZH2 as an oncogene, it must be stated that in particular cellular environments the picture becomes less clear, like for example in malignant myeloid diseases. Three different reports showed the inactivation of EZH2 in myelodysplastic syndromes (MDSs) and in myeloproliferative disorder (MPD) [203-205]. Point mutations of EZH2 gene in MDSs, MPD, and primary myelofibrosis (PMF) are predictors of poor overall survival, independently by risk factors [206,207]. Similarly, three studies conducted in T-acute lymphoblastic leukemia (T-ALL) demonstrated that PRC2 displays a tumor suppressor role in this pathology [171,208,209]. Particularly, Simon and colleagues demonstrated that in mouse, loss of EZH2 in hematopoietic stem cells induces aggressive T-ALL. Similar studies in human showed a comparable decrease of EZH2 levels in T-ALL [171]. Moreover, Ntziachristos and coworkers found that EZH2 and other PRC2 core components are frequently mutated in T-ALL samples [209]. Of interest is that the frequency of PRC2 mutations is higher in pediatric subtype of leukemia [208].

Despite mutations of EZH2 seem specific for a few type of cancers, latest reports suggest a fine balance of H3K27 methylation, necessary for normal cell growth. Recent studies showed an indirect EZH2-dependent mechanism involved in pancreatic cancer inhibition. Jon Mallen-St. and co-authors investigated the role of EZH2 in pancreatic regeneration and in cancer progression using a mouse model characterized by KRas activation, frequently mutated in pancreatic tumors. In particular, they show that KRas mutated mice developed preneoplastic lesions but rarely progressed into invasive adenocarcinoma. The loss

of EZH2 function in this experimental model increases by 6 times the development of pancreatic intraepithelial neoplasia, suggesting a protective role of EZH2 in pancreatic carcinogenesis. Since EZH2 is transiently upregulated after injury and returns to basal levels after tissue recovery, it has been proposed that, in injured tissue, surviving acinar cells de-differentiate into metaplastic epithelial intermediates are able to proliferate and restore pancreatic injury. Proliferation is induced by EZH2 activation through P16INK4a inhibition. Subsequently, acinar cell mass and function is finally restored through re-differentiation, which corresponds to restored basal levels of EZH2. EZH2 is involved therefore in homeostatic mechanisms that controls pancreatic regeneration, decreasing the risk of pancreatic cancer in patient with chronic pancreatic injury [156,184].

6. Conclusions

Epigenetic alterations in cancer cells represent an important aspect of tumor biology. Differently from genetic modifications, epigenetic alterations can be reversed by specific drugs inducing the restoration of “normal” cellular pathways, which in turn promote cellular senescence or apoptosis. Therefore, epigenetic changes are excellent target candidates for chemotherapeutic intervention in cancer.

Several HDAC and DNMT inhibitors are already available as putative anticancer drugs, and several clinical trials are underway [210,211].

A pharmacological therapy, which specifically targets EZH2, may constitute a novel approach to the treatment of cancer, assuming its role in inhibition of several tumor suppressor or differentiation genes.

Recently, an S-adenosyl-L-homocysteine (AdoHcy) hydrolase inhibitor, 3-Deazaneplanocin A (DZNep), has been demonstrated to deplete EZH2 and remove H3K27me3 at PRC2 target genes. The inhibition of AdoHcy hydrolase fosters accumulation of AdoHcy, which in turn stops S-adenosyl-L-methionine (SAH)-dependent methyltransferases.

DZNep promotes apoptosis in cancer cell lines as breast and colorectal cancer cells, but not in normal cells. DZNep reduces cellular levels of PRC2 subunits, inhibits H3K27 methylation and promotes the reactivation of PRC2 silenced genes and apoptosis [212]

Of interest is that, in several non-small cell lung cancer (NSCLC) cell lines, DZNep treatment results in p27 accumulation, G1 cell cycle arrest and apoptosis, whereas immortalized bronchial epithelial and fibroblast cell lines are less sensitive and show apoptosis with lesser extent, which render it a potential candidate in anti-cancer therapy [160].

Studies in various gastric cancer cell lines and in primary human gastric cancer cells showed that the DZNep responsiveness is attenuated in p53-depleted cells. p53 genomic status is therefore a potential predictive marker of DZNep response in this specific cell type [213].

Despite its potential usefulness in cancer therapy, further studies need to address its target specificity. Indeed, it has been reported that DZNep inhibits H4K20 methylation, another

epigenetic modification, which is involved with chromosome stability [212]. The effect of DZNep on several methyl transferases activity is a strong limiting factor for its use as anti-cancer drug.

New PRC2 targets have been recently developed. GSK126 is a small molecule, competitor of S-adenosyl-L-methionine. Unlike DZNep, that reduce levels of EZH2 indirectly, GSK126 specifically inhibits EZH2 methyltransferase activity with no alterations in EZH2 expression. In lymphoma cells, GSK126 treatment decreases global H3K27me3 levels and reactivates PRC2 target genes. [169]. Finally, it has been discovered a natural compound, 16-hydroxyclo-*da-3,13-dien-15,16-olide* (PL3), which is able to promote apoptosis in leukemia K562 cells by the modulation of various histone-modifying enzymes among which EZH2 and SUZ12 [214].

Other studies are needed to design inhibitors specific for PRC2 and to develop new strategies for epigenetic therapy in cancer.

Acknowledgements

We are grateful to Dr. Francesco Paolo Fiorentino for his helpful comments on this manuscript.

This work was supported by a grant from POR FSE 2007–2013 “Regione Autonoma della Sardegna, Programma Master and Back” and a grant from “Fondazione Banco di Sardegna” (Rif. Vs Prot. 469/2011.271).

Author details

Irene Marchesi¹ and Luigi Bagella^{1,2}

1 Department of Biomedical Sciences, Division of Biochemistry and National Institute of Biostructures and Biosystems, University of Sassari, Sassari, Italy

2 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, USA

References

- [1] Van Speybroeck L. From epigenesis to epigenetics: the case of C. H. Waddington. *Annals New York Academy of Sciences* 2002;981: 61–81.
- [2] Feinberg AP, Tycko B. The history of cancer epigenetics. *Nature Review Cancer* 2004;4(2): 143–53.

- [3] Grunstein M. Yeast heterochromatin: regulation of its assembly and inheritance by histones. *Cell* 1998;93(3): 325–8.
- [4] Turner BM. Histone acetylation as an epigenetic determinant of long-term transcriptional competence. *Cellular and Molecular Life Sciences* 1998;54(1): 21–31.
- [5] Strahl BD, Allis CD. The language of covalent histone modifications. *Nature* 2000;403(6765): 41–5.
- [6] Karpen GH, Allshire RC. The case for epigenetic effects on centromere identity and function. *Trends in Genetics* 1997;13(12): 489–96.
- [7] Wei Y, Yu L, Bowen J, Gorovsky MA, Allis CD. Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. *Cell* 1999;97(1): 99–109.
- [8] Berger SL. The complex language of chromatin regulation during transcription. *Nature* 2007;447(7143): 407–12.
- [9] Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. *Nature Reviews Molecular and Cellular Biology* 2009;10(3): 192–206.
- [10] Bird A. DNA methylation patterns and epigenetic memory. *Genes & Development* 2002;16(1): 6–21.
- [11] Fiorentino FP, Marchesi I, Giordano A. On the role of Retinoblastoma family proteins in the establishment and maintenance of the epigenetic landscape. *Journal of Cellular Physiology* 2013;228(2): 276–84.
- [12] Liang G, Chan MF, Tomigahara Y, Tsai YC, Gonzales FA, Li E, et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. *Molecular and Cellular Biology* 2002;22(2): 480–91.
- [13] Chen T, Ueda Y, Dodge JE, Wang Z, Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. *Molecular and Cellular Biology* 2003;23(16): 5594–605.
- [14] Riggs AD, Xiong Z. Methylation and epigenetic fidelity. *Proceedings of the National Academy of Sciences* 2004;101(1): 4–5.
- [15] Jeong S, Liang G, Sharma S, Lin JC, Choi SH, Han H, et al. Selective Anchoring of DNA Methyltransferases 3A and 3B to Nucleosomes Containing Methylated DNA. *Molecular and Cellular Biology* 2009;29(19): 5366–76.
- [16] Ooi SKT, Bestor TH. The Colorful History of Active DNA Demethylation. *Cell* 2008;133(7): 1145–8.
- [17] Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. *Cell* 2008;135(7): 1201–12.

- [18] Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, et al. Thymine DNA Glycosylase Is Essential for Active DNA Demethylation by Linked Deamination-Base Excision Repair. *Cell* 2011;146(1): 67–79.
- [19] Métivier R, Gallais R, Tiffocche C, Le Péron C, Jurkowska RZ, Carmouche RP, et al. Cyclical DNA methylation of a transcriptionally active promoter. *Nature* 2008;452(7183): 45–50.
- [20] Kangaspeska S, Stride B, Métivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, et al. Transient cyclical methylation of promoter DNA. *Nature* 2008;452(7183): 112–5.
- [21] Kim M-S, Kondo T, Takada I, Youn M-Y, Yamamoto Y, Takahashi S, et al. DNA demethylation in hormone-induced transcriptional derepression. *Nature* 2009;461(7266): 1007–12.
- [22] Cohen NM, Dighe V, Landan G, Reynisdottir S, Palsson A, Mitalipov S, et al. DNA methylation programming and reprogramming in primate embryonic stem cells. *Genome Research* 2009;19(12): 2193–201.
- [23] Kouzarides T. Chromatin Modifications and Their Function. *Cell* 2007;128(4): 693–705.
- [24] Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. *Nature* 2007;447(7143): 425–32.
- [25] Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. *Nature Review Genetics* 2006;7(1): 21–33.
- [26] Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nature Review Genetics* 2002;3(6): 415–28.
- [27] Ting AH, McGarvey KM, Baylin SB. The cancer epigenome--components and functional correlates. *Genes & Development* 2006;20(23): 3215–31.
- [28] Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. *Nature Review Cancer* 2006;6(11): 846–56.
- [29] Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. *Nature Review Genetics* 2007;8(4): 286–98.
- [30] Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. *Nature Genetics* 2005;37(4): 391–400.
- [31] Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. *Nature Cell Biology* 2005;435(7046): 1262–6.

- [32] Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. *Mutation Research* 2008;647(1-2): 21–9.
- [33] Lewis EB. A gene complex controlling segmentation in *Drosophila*. *Nature* 1978;276(5688): 565–70.
- [34] Struhl G. A gene product required for correct initiation of segmental determination in *Drosophila*. *Nature* 1981;293(5827): 36–41.
- [35] Duncan IM. Polycomblike: a gene that appears to be required for the normal expression of the bithorax and antennapedia gene complexes of *Drosophila melanogaster*. *Genetics* 1982;102(1): 49–70.
- [36] Jurgens G. A Group of Genes-Controlling the Spatial Expression of the Bithorax Complex in *Drosophila*. *Nature* 1985;316(6024): 153–5.
- [37] Schwartz YB, Kahn TG, Nix DA, Li X-Y, Bourgon R, Biggin M, et al. Genome-wide analysis of Polycomb targets in *Drosophila melanogaster*. *Nature Genetics* 2006;38(6): 700–5.
- [38] Nègre N, Hennetin J, Sun LV, Lavrov S, Bellis M, White KP, et al. Chromosomal Distribution of PcG Proteins during *Drosophila* Development. *Plos Biology* 2006;4(6): e170.
- [39] Tolhuis B, Muijters I, de Wit E, Teunissen H, Talhout W, van Steensel B, et al. Genome-wide profiling of PRC1 and PRC2 Polycomb chromatin binding in *Drosophila melanogaster*. *Nature Genetics* 2006;38(6): 694–9.
- [40] Oktaba K, Gutiérrez L, Gagneur J, Girardot C, Sengupta AK, Furlong EEM, et al. Dynamic Regulation by Polycomb Group Protein Complexes Controls Pattern Formation and the Cell Cycle in *Drosophila*. *Developmental Cell* 2008;15(6): 877–89.
- [41] Kwong C, Adryan B, Bell I, Meadows L, Russell S, Manak JR, et al. Stability and Dynamics of Polycomb Target Sites in *Drosophila* Development. *PLoS Genetics* 2008;4(9): e1000178.
- [42] Schuettengruber B, Cavalli G. Recruitment of Polycomb group complexes and their role in the dynamic regulation of cell fate choice. *Development* 2009;136(21): 3531–42.
- [43] Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. *Genes & Development* 2004;18(13): 1592–605.
- [44] Bracken AP. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. *Genes & Development* 2006;20(9): 1123–36.
- [45] Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. *Nature Cell Biology* 2006;441(7091): 349–53.

- [46] Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells. *Cell* 2006;125(2): 301–13.
- [47] Squazzo SL. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. *Genome Research* 2006;16(7): 890–900.
- [48] Simon JA, Kingston RE. Mechanisms of Polycomb gene silencing: knowns and unknowns. *Nature Review Molecular Cell Biology* 2009;10(10): 697–708.
- [49] Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, et al. Role of histone H3 lysine 27 methylation in X inactivation. *Science* 2003;300(5616): 131–5.
- [50] Umlauf D, Goto Y, Cao R, Cerqueira F, Wagschal A, Zhang Y, et al. Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. *Nature Genetics* 2004;36(12): 1296–300.
- [51] Pietersen AM, van Lohuizen M. Stem cell regulation by polycomb repressors: postponing commitment. *Current Opinion in Cell Biology* 2008;20(2): 201–7.
- [52] Morey L, Helin K. Polycomb group protein-mediated repression of transcription. *Trends in Biochemical Sciences* 2010;35(6): 323–32.
- [53] Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. *Nature* 2011;469(7330): 343–9.
- [54] Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. *Molecular and Cellular Biology* 2002;22(17): 6070–8.
- [55] Shao Z, Raible F, Mollaaghababa R, Guyon J, Wu C, Bender W, et al. Stabilization of Chromatin Structure by PRC1, a Polycomb Complex. *Cell* 1999;98(1): 37–46.
- [56] Cao R. Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing. *Science* 2002;298(5595): 1039–43.
- [57] Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. *Cell* 2002;111(2): 185–96.
- [58] Kuzmichev A. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. *Genes & Development* 2002;16(22): 2893–905.
- [59] Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. *Cell* 2002;111(2): 197–208.

- [60] Surface LE, Thornton SR, Boyer LA. Polycomb Group Proteins Set the Stage for Early Lineage Commitment. *Cell Stem Cell* 2010;7(3): 288–98.
- [61] Cao R, Zhang Y. SUZ12 Is Required for Both the Histone Methyltransferase Activity and the Silencing Function of the EED-EZH2 Complex. *Molecular Cell* 2004;15(1): 57–67.
- [62] Pasini D, Bracken AP, Helin K. Polycomb group proteins in cell cycle progression and cancer. *Cell Cycle* 2004;3(4): 396–400.
- [63] Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. *Molecular Cell* 2008;32(4): 503–18.
- [64] Shen X, Liu Y, Hsu Y-J, Fujiwara Y, Kim J, Mao X, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. *Molecular Cell* 2008;32(4): 491–502.
- [65] Aldiri I, Vetter ML. PRC2 during vertebrate organogenesis: A complex in transition. *Developmental Biology* 2012;367(2): 91–9.
- [66] Leeb M, Pasini D, Novatchkova M, Jaritz M, Helin K, Wutz A. Polycomb complexes act redundantly to repress genomic repeats and genes. *Genes & Development* 2010;24(3): 265–76.
- [67] Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, et al. Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains. van Steensel B, editor. *PLoS Genetics* 2008;4(10): e1000242.
- [68] Wang L, Brown JL, Cao R, Zhang Y, Kassis JA, Jones RS. Hierarchical Recruitment of Polycomb Group Silencing Complexes. *Molecular Cell* 2004;14(5): 637–46.
- [69] Cao R, Tsukada Y-I, Zhang Y. Role of Bmi-1 and Ring1A in H2A Ubiquitylation and Hox Gene Silencing. *Molecular Cell* 2005;20(6): 845–54.
- [70] Eskeland R, Leeb M, Grimes GR, Kress C, Boyle S, Sproul D, et al. Ring1B Compacts Chromatin Structure and Represses Gene Expression Independent of Histone Ubiquitination. *Molecular Cell* 2010;38(3): 452–64.
- [71] Richly H, Aloia L, Di Croce L. Roles of the Polycomb group proteins in stem cells and cancer. *Cell Death and Disease* 2012;2(9): e204–7.
- [72] Kuzmichev A, Jenuwein T, Tempst P, Reinberg D. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. *Molecular Cell* 2004;14(2): 183–93.
- [73] Daujat S. HP1 Binds Specifically to Lys26-methylated Histone H1.4, whereas Simultaneous Ser27 Phosphorylation Blocks HP1 Binding. *Journal of Biological Chemistry* 2005;280(45): 38090–5.

- [74] Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. *Nature Cell Biology* 2005;439(7078): 871–4.
- [75] Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. *Nature Genetics* 2007;39(2): 237–42.
- [76] Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. *Nature Genetics* 2006;39(2): 232–6.
- [77] Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. *Nature Genetics* 2006;39(2): 157–8.
- [78] van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. *Nature Genetics* 1999;23(4): 474–8.
- [79] Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature* 2002;419(6907): 624–9.
- [80] Kerppola TK. Polycomb group complexes – many combinations, many functions. *Trends in Cell Biology* 2009;19(12): 692–704.
- [81] Bracken AP, Helin K. Epigenetics and genetics: Polycomb group proteins: navigators of lineage pathways led astray in cancer. *Nature Review Cancer* 2009;9(11): 773–84
- [82] Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ. Use of chromatin immunoprecipitation to clone novel E2F target promoters. *Molecular and Cellular Biology* 2001;21(20): 6820–32.
- [83] Müller HH, Bracken APA, Vernell RR, Moroni MCM, Christians FF, Grassilli EE, et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. *Genes & Development* 2001;15(3): 267–85.
- [84] Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. *EMBO Journal* 2003;22(20): 5323–35.
- [85] Neri F, Zippo A, Krepelova A, Cherubini A, Rocchigiani M, Oliviero S. Myc Regulates the Transcription of the PRC2 Gene To Control the Expression of Developmental Genes in Embryonic Stem Cells. *Molecular and Cellular Biology* 2012;32(4): 840–51.
- [86] Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: Tying it all together. *The International Journal of Biochemistry & Cell Biology* 2009;41(1): 87–95.

- [87] Benetatos L, Voulgaris E, Vartholomatos G, Hatzimichael E. Non coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome. *International Journal of Cancer* 2012; doi: 10.1002/ijc.27859.
- [88] Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Mir-214-Dependent Regulation of the Polycomb Protein Ezh2 in Skeletal Muscle and Embryonic Stem Cells. *Molecular Cell* 2009;36(1): 61–74.
- [89] Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, et al. Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2. *Journal of Clinical Endocrinology & Metabolism* 2012;97(5): e710–8.
- [90] Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, et al. Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM. *PLoS ONE* 2012;7(3): e33729.
- [91] Riising EM, Boggio R, Chiocca S, Helin K, Pasini D. The Polycomb Repressive Complex 2 Is a Potential Target of SUMO Modifications. *PLoS ONE* 2008;3(7): e2704.
- [92] Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. *Nature Cell Biology* 2010;12(11): 1108–14.
- [93] Kaneko S, Li G, Son J, Xu CF, Margueron R, Neubert TA, et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. *Genes & Development* 2010;24(23): 2615–20.
- [94] Caretti G, Palacios D, Sartorelli V, Puri PL. Phosphoryl-EZH-ion. *Cell Stem Cell* 2011;8(3): 262–5.
- [95] Wei Y, Chen Y-H, Li L-Y, Lang J, Yeh S-P, Bin Shi, et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. *Nature Cell Biology* 2010;13(1): 87–94.
- [96] Cha T-LT, Zhou BPB, Xia WW, Wu YY, Yang C-CC, Chen C-TC, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. *Science* 2005;310(5746): 306–10.
- [97] Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V, et al. TNF/ α /Polycomb Signaling to Pax7 Locus in Satellite Cells Links Inflammation to the Epigenetic Control of Muscle Regeneration. *Stem Cell* 2010;7(4): 455–69.
- [98] Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury WJ III, et al. Role of the polycomb protein EED in the propagation of repressive histone marks. *Nature* 2009;461(7265): 762–7.
- [99] Ringrose L, Paro R. Polycomb/Trithorax response elements and epigenetic memory of cell identity. *Development* 2007;134(2): 223–32.

- [100] Müller J, Kassis JA. Polycomb response elements and targeting of Polycomb group proteins in *Drosophila*. *Current Opinion in Genetics & Development* 2006;16(5): 476–84.
- [101] Sing A, Pannell D, Karaïskakis A, Sturgeon K, Djabali M, Ellis J, et al. A Vertebrate Polycomb Response Element Governs Segmentation of the Posterior Hindbrain. *Cell* 2009;138(5): 885–97.
- [102] Van Dessel N, Beke L, Gornemann J, Minnebo N, Beullens M, Tanuma N, et al. The phosphatase interactor NIPP1 regulates the occupancy of the histone methyltransferase EZH2 at Polycomb targets. *Nucleic Acids Research* 2010;38(21): 7500–12.
- [103] Cakouros D, Isenmann S, Cooper L, Zannettino A, Anderson P, Glackin C, et al. Twist-1 Induces Ezh2 Recruitment Regulating Histone Methylation along the Ink4A/Arf Locus in Mesenchymal Stem Cells. *Molecular and Cellular Biology* 2012;32(8): 1433–41.
- [104] Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D. Ezh2 Requires PHF1 To Efficiently Catalyze H3 Lysine 27 Trimethylation In Vivo. *Molecular and Cellular Biology* 2008;28(8): 2718–31.
- [105] Cao R, Wang H, He J, Erdjument-Bromage H, Tempst P, Zhang Y. Role of hPHF1 in H3K27 Methylation and Hox Gene Silencing. *Molecular and Cellular Biology* 2008;28(5): 1862–72.
- [106] Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A, et al. Jarid2/Jumonji Coordinates Control of PRC2 Enzymatic Activity and Target Gene Occupancy in Pluripotent Cells. *Cell* 2009;139(7): 1290–302.
- [107] Shen X, Kim W, Fujiwara Y, Simon MD, Liu Y, Mysliwiec MR, et al. Jumonji Modulates Polycomb Activity and Self-Renewal versus Differentiation of Stem Cells. *Cell* 2009;139(7): 1303–14.
- [108] Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. Jarid2 and PRC2, partners in regulating gene expression. *Genes & Development* 2010;24(4): 368–80.
- [109] Pasini D, Cloos PAC, Walfridsson J, Olsson L, Bukowski J-P, Johansen JV, et al. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. *Nature* 2010;464(7286): 306–10.
- [110] Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proceedings of the National Academy of Sciences* 2009;106(28): 11667–72.
- [111] Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell* 2007;129(7): 1311–23.

- [112] Pauli A, Rinn JL, Schier AF. Non-coding RNAs as regulators of embryogenesis. *Nature Review Genetics* 2011;12(2): 136–49.
- [113] Sher F, Rössler R, Brouwer N, Balasubramaniyan V, Boddeke E, Copray S. Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2. *Stem Cells* 2008;26(11): 2875–83.
- [114] Hirabayashi Y, Suzuki N, Tsuboi M, Endo TA, Toyoda T, Shinga J, et al. Polycomb Limits the Neurogenic Competence of Neural Precursor Cells to Promote Astrogenic Fate Transition. *Neuron* 2009;63(5): 600–13.
- [115] Pereira JD, Sansom SN, Smith J, Dobenecker M-W, Tarakhovsky A, Livesey FJ. Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex. *Proceedings of the National Academy of Sciences* 2010;107(36): 15957–62.
- [116] Yu YL, Chou RH, Chen LT, Shyu WC, Hsieh SC, Wu CS, et al. EZH2 Regulates Neuronal Differentiation of Mesenchymal Stem Cells through PIP5K1C-dependent Calcium Signaling. *Journal of Biological Chemistry* 2011;286(11): 9657–67.
- [117] Sher F, Boddeke E, Copray S. Ezh2 Expression in Astrocytes Induces Their Dedifferentiation Toward Neural Stem Cells. *Cellular Reprogramming* 2011;13(1): 1–6.
- [118] Sher F, Boddeke E, Olah M, Copray S. Dynamic Changes in Ezh2 Gene Occupancy Underlie Its Involvement in Neural Stem Cell Self-Renewal and Differentiation towards Oligodendrocytes. *PLoS ONE* 2012;7(7): e40399.
- [119] Akizu N, Estaras C, Guerrero L, Marti E, Martinez-Balbas MA. H3K27me3 regulates BMP activity in developing spinal cord. *Development* 2010;137(17): 2915–25.
- [120] Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su I-H, Hannon G, et al. Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells. *Cell* 2009;136(6): 1122–35.
- [121] Ezhkova E, Lien WH, Stokes N, Pasolli HA, Silva JM, Fuchs E. EZH1 and EZH2 co-govern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. *Genes & Development* 2011;25(5): 485–98.
- [122] Mulder KW, Wang X, Escribe C, Ito Y, Schwarz RF, Gillis J, et al. Diverse epigenetic strategies interact to control epidermal differentiation. *Nature Cell Biology* 2012;14(7): 753–63.
- [123] Delgado-Olguín P, Huang Y, Li X, Christodoulou D, Seidman CE, Seidman JG, et al. Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. *Nature Genetics* 2012;44(3): 343–7.
- [124] He M, Zhang W, Bakken T, Schutten M, Toth Z, Jung JU, et al. Cancer angiogenesis induced by Kaposi's sarcoma-associated herpesvirus is mediated by EZH2. *Cancer Research* 2012;72(14): 3582–92.

- [125] Chen L, Ma Y, Kim EY, Yu W, Schwartz RJ, Qian L, et al. Conditional Ablation of Ezh2 in Murine Hearts Reveals Its Essential Roles in Endocardial Cushion Formation, Cardiomyocyte Proliferation and Survival. *PLoS ONE* 2012;7(2): e31005.
- [126] Caretti G. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. *Genes & Development* 2004;18(21): 2627–38.
- [127] Seenundun S, Rampalli S, Liu Q-C, Aziz A, Palii C, Hong S, et al. UTX mediates demethylation of H3K27me3 at muscle-specific genes during myogenesis. *EMBO Journal* 2010;29(8): 1401–11.
- [128] Juan AH, Derfoul A, Feng X, Ryall JG, Dell'Orso S, Pasut A, et al. Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. *Genes & Development* 2011;25(8): 789–94.
- [129] Stojic L, Jasencakova Z, Prezioso C, Stützer A, Bodega B, Pasini D, et al. Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells. *Epigenetics & Chromatin* 2011;4(1): 16.
- [130] Aoki R, Chiba T, Miyagi S, Negishi M, Konuma T, Taniguchi H, et al. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. *Journal of Hepatology* 2010;52(6): 854–63.
- [131] Xu C, Bian C, Yang W, Galka M, Ouyang H, Chen C, et al. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). *Proceedings of the National Academy of Sciences* 2010;107(45): 19266–71.
- [132] Chen H, Gu X, Su I-H, Bottino R, Contreras JL, Tarakhovsky A, et al. Polycomb protein Ezh2 regulates pancreatic -cell Ink4a/Arf expression and regeneration in diabetes mellitus. *Genes & Development* 2009;23(8): 975–85.
- [133] Xu CR, Cole PA, Meyers DJ, Kormish J, Dent S, Zaret KS. Chromatin “Prepattern” and Histone Modifiers in a Fate Choice for Liver and Pancreas. *Science* 2011;332(6032): 963–6.
- [134] Wang L, Jin Q, Lee JE, Su I-H, Ge K. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. *Proceedings of the National Academy of Sciences* 2010;107(16): 7317–22.
- [135] Shore AN, Kabotyanski EB, Roarty K, Smith MA, Zhang Y, Creighton CJ, et al. Pregnancy-Induced Noncoding RNA (PIN) Associates with Polycomb Repressive Complex 2 and Regulates Mammary Epithelial Differentiation. *PLoS Genetics* 2012;8(7): e1002840.
- [136] Gil J, Bernard D, Martínez D, Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. *Nature Cell Biology* 2003;6(1): 67–72.

- [137] Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. *Nature* 2004;428(6980): 337–41.
- [138] Bruggeman SWM. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. *Genes & Development* 2005;19(12): 1438–43.
- [139] Gil J, Peters G. Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all. *Nature Review Molecular Cell Biology* 2006;7(9): 667–77.
- [140] Dietrich N, Bracken AP, Trinh E, Schjerling CK, Koseki H, Rappsilber J, et al. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. *EMBO Journal* 2007;26(6): 1637–48.
- [141] Dhawan S, Tschen SI, Bhushan A. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic -cell proliferation. *Genes & Development* 2009;23(8): 906–11.
- [142] Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells. *Cell* 2006;125(2): 315–26.
- [143] Puri PL, Sartorelli V. Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. *Journal of Cellular Physiology* 2000;185(2): 155–73.
- [144] Mousavi K, Zare H, Wang AH, Sartorelli V. Polycomb Protein Ezh1 Promotes RNA Polymerase II Elongation. *Molecular Cell* 2012;45(2): 255–62.
- [145] Gaudet F. Induction of Tumors in Mice by Genomic Hypomethylation. *Science* 2003;300(5618): 489–92.
- [146] Feinberg AP. Epigenetics at the epicenter of modern medicine. *JAMA: The journal of the American Medical Association* 2008;299(11): 1345–50.
- [147] Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proceedings of the National Academy of Sciences* 2003;100(20): 11606–11.
- [148] Raaphorst FMF, Meijer CJLMC, Fieret EE, Blokzijl TT, Mommers EE, Buerger HH, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. *Neoplasia* 2003;5(6): 481–8.
- [149] Bachmann IM. EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast. *Journal of Clinical Oncology* 2005;24(2): 268–73.
- [150] Collett K. Expression of Enhancer of Zeste Homologue 2 Is Significantly Associated with Increased Tumor Cell Proliferation and Is a Marker of Aggressive Breast Cancer. *Clinical Cancer Research* 2006;12(4): 1168–74.

- [151] Ding L. Identification of EZH2 as a Molecular Marker for a Precancerous State in Morphologically Normal Breast Tissues. *Cancer Research* 2006;66(8): 4095–9.
- [152] Rhodes DRD, Sanda MGM, Otte APA, Chinnaiyan AMA, Rubin MAM. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. *Journal of the National Cancer Institute* 2003;95(9): 661–8.
- [153] Saramäki OR, Tammela TLJ, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. *Genes Chromosomes and Cancer* 2006;45(7): 639–45.
- [154] Berezovska OPO, Glinskii ABA, Yang ZZ, Li X-MX, Hoffman RMR, Glinsky GVG. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. *Cell Cycle* 2006;5(16): 1886–901.
- [155] van Leenders GJLH, Dukers D, Hessels D, van den Kieboom SWM, Hulsbergen CA, Witjes JA, et al. Polycomb-Group Oncogenes EZH2, BMI1, and RING1 Are Overexpressed in Prostate Cancer With Adverse Pathologic and Clinical Features. *European Urology* 2007;52(2): 455–63.
- [156] Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A, Pylayeva-Gupta Y, et al. EZH2 couples pancreatic regeneration to neoplastic progression. *Genes & Development* 2012;26(5): 439–44.
- [157] Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, et al. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. *Prostate* 2012; doi: 10.1002/pros.22587.
- [158] Breuer RHJ, Snijders PJF, Smit EF, Sutedja TG, Sewalt RGAB, Otte AP, et al. Increased Expression of the EZH2 Polycomb Group Gene in BMI-1-Positive Neoplastic Cells During Bronchial Carcinogenesis. *Neoplasia* 2004;6(6): 736–43.
- [159] McCabe MT, Brandes JC, Vertino PM. Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications. *Clinical Cancer Research* 2009;15(12): 3927–37.
- [160] Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. *Lung Cancer* 2012;78(2): 138–43.
- [161] Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. *European Journal of Surgical Oncology* 2005;31(4): 376–80.
- [162] Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. *British Journal of Cancer* 2005;92(9): 1754–8.

- [163] Au SL-K, Wong CC-L, Lee JM-F, Fan DN-Y, Tsang FH, Ng IO-L, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. *Hepatology* 2012;56(2): 622-31.
- [164] Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. *Cancer Science* 2006;97(6): 484-91.
- [165] van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, et al. Co-expression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. *Blood* 2001;97(12): 3896-901.
- [166] Visser HPJ, Gunster MJ, Kluin Nelemans HC, Manders EMM, Raaphorst FM, Meijer CJLM, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. *British journal of haematology* 2001;112(4): 950-8.
- [167] Park SW, Chung NG, Eom HS, Yoo NJ, Lee SH. Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias. *Leukemia Research* 2010;35(1): e6-7.
- [168] Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nature Genetics* 2010;42(2): 181-5.
- [169] McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* 2012; doi: 10.1038/nature11606.
- [170] Chen J, Li J, Han Q, Sun Z, Wang J, WANG S, et al. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia. *Experimental Biology and Medicine* 2012;237(9): 1110-6.
- [171] Simon C, Chagraoui J, Kros J, Gendron P, Wilhelm B, Lemieux S, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. *Genes & Development* 2012;26(7): 651-6.
- [172] Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. *Oncogene* 2005;24(41): 6269-80.
- [173] Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. *Blood* 2012;120(5): 1107-17.
- [174] Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. *Proceedings of the National Academy of Sciences* 2012;109(13): 5028-33.

- [175] Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, et al. Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2. *Molecular Cancer Therapeutics* 2011;10(2): 325–35.
- [176] McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. Expression of polycomb group protein EZH2 in nevi and melanoma. *Journal of Cutaneous Pathology* 2007;34(8): 597–600.
- [177] Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. *Oncotarget* 2012 3(9): 1011-25.
- [178] Raman JD. Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder. *Clinical Cancer Research* 2005;11(24): 8570–6.
- [179] Zhou J, Roh J-W, Bandyopadhyay S, Chen Z, Munkarah A, Hussein Y, et al. Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. *Gynecologic Oncology* 2012; <http://dx.doi.org/10.1016/j.ygyno.2012.07.128>.
- [180] Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, et al. De-regulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. *Cell Cycle* 2009;8(1): 172–5.
- [181] Venneti S, Le P, Martinez D, Xie SX, Sullivan LM, Rorke-Adams LB, et al. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins. *The American Journal of Surgical Pathology* 2011;35(10): 1463–72.
- [182] Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. *Cell Cycle* 2012;11(20): 3828–36.
- [183] Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells. *Molecular Cancer Therapeutics* 2012;11(8): 1735-46.
- [184] Lasfargues C, Pyronnet S. EZH2 links pancreatitis to tissue regeneration and pancreatic cancer. *Clinics and Research in Hepatology and Gastroenterology* 2012;36(4): 323-4
- [185] Shen Y, Guo X, Wang Y, Qiu W, Chang Y, Zhang A, et al. Expression and significance of histone H3K27 demethylases in renal cell carcinoma. *BMC Cancer* 2012;12(1):470.
- [186] Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, et al. EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance. *Cancer Research*;69(24): 9211–8.

- [187] Smits M, van Rijn S, Hulleman E, Biesmans D, van Vuurden DG, Kool M, et al. EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival. *Clinical Cancer Research* 2012;18(15): 4048-58.
- [188] Molofsky AV. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. *Genes & Development* 2005;19(12): 1432-7.
- [189] Fiorentino FP, Symonds CE, Macaluso M, Giordano A. Senescence and p130/Rbl2: a new beginning to the end. *Cell Research* 2009;19(9): 1044-51.
- [190] Sherr CJ. The INK4a/ARF network in tumour suppression. *Nature Review Molecular Cell Biology* 2001;2(10): 731-7.
- [191] Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. *Current Opinion in Genetics & Development* 2003;13(1): 77-83.
- [192] Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene. *Genes & Development* 2007;21(1): 49-54.
- [193] Tonini T, Bagella L, D'andrilli G, Claudio PP, Giordano A. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. *Oncogene* 2004;23(28): 4930-7.
- [194] Tonini T, D'andrilli G, Fucito A, Gaspa L, Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. *Journal of Cellular Physiology* 2007;214(2): 295-300.
- [195] Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CCR, et al. EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression. *Molecular Cancer Research* 2011;9(4): 418-29.
- [196] Chen H. Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer. *Journal of Biological Chemistry* 2005;280(23): 22437-44.
- [197] Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. *Cell Death and Differentiation* 2009;17(5): 801-10.
- [198] Su I-H, Dobenecker M-W, Dickinson E, Oser M, Basavaraj A, Marqueron R, et al. Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling. *Cell* 2005;121(3): 425-36.
- [199] Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. *Prostate* 2007;67(5): 547-56.

- [200] Bryant RJ, Winder SJ, Cross SS, Hamdy FC, Cunliffe VT. The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells. *Prostate* 2008;68(3): 255–63.
- [201] Martinez-Garcia E, Licht JD. Deregulation of H3K27 methylation in cancer. *Nature Genetics* 2010;42(2): 100–1.
- [202] Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. Co-ordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. *Proceedings of the National Academy of Sciences* 2010;107(49): 20980–5.
- [203] Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. *Nature Genetics* 2010;42(8): 722–6.
- [204] Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, Tönnissen ERLTM, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. *Nature Genetics* 2010;42(8): 665–7.
- [205] Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. *Leukemia* 2010;24(10): 1799–804.
- [206] Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical Effect of Point Mutations in Myelodysplastic Syndromes. *The New England Journal of Medicine* 2011;364(26): 2496–506.
- [207] Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, et al. EZH2 mutational status predicts poor survival in myelofibrosis. *Blood* 2011;118(19): 5227–34.
- [208] Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* 2012;481(7380): 157–63.
- [209] Ntziachristos P, Tsirigos A, Vlierberghe PV, Nedjic J, Trimarchi T, Flaherty MS, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. *Nature Medicine* 2012;18(2): 298–303.
- [210] Lyko F, Brown R. DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies. *Journal of the National Cancer Institute* 2005;97(20): 1498–506.
- [211] Federico M, Bagella L. Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors. *Journal of Biomedicine and Biotechnology* 2011; doi:10.1155/2011/475641

- [212] Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. *Genes & Development* 2007;21(9): 1050–63.
- [213] Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, et al. TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). *Clinical Cancer Research* 2012;18(15): 4201-12.
- [214] Lin Y-H, Lee C-C, Chang F-R, Chang W-H, Wu Y-C, Chang J-G. 16-Hydroxycyclo-oct-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells. *Life Sciences* 2011;89(23-24): 886-95.